News | 09 September 2024
Suspected Mpox case under investigation
The patient has been isolated in a designated hospital and is currently stable
The patient has been isolated in a designated hospital and is currently stable
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
Effective, holistic, science-backed targeted solutions for symptomatic treatment
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Subscribe To Our Newsletter & Stay Updated
